Archived ASX Releases
Also in this
2016 ASX Releases
2015 ASX Releases
2014 ASX Releases
2013 ASX Releases
2012 ASX Releases
2011 ASX Releases
2010 ASX Releases
2009 ASX Releases
2008 ASX Releases
CSL Historical Financial Performance in US Dollars
In February 2012, the company announced its decision to move to US dollar reporting commencing with the 2012/13 financial year. US dollars are the pharmaceutical industry standard currency for reporting purposes. The move also reflects the increasing predominance of the Company’s worldwide sales and operations in US dollars.
Full Year Results Announcement for 2011/12
CSL Limited (ASX:CSL) today announced a net profit after tax of A$983 million for the twelve months ended 30 June 2012, up A$42 million or 4.5% on a reported basis when compared to the prior comparable period. This result included an unfavourable foreign exchange impact of A$108 million.
Successor to CEO Brian McNamee Announced
CSL Limited (ASX:CSL) - CSL Chairman, Professor John Shine, AO, today announced that after 23 years at the helm of CSL, Dr Brian McNamee, AO, has agreed with the Board of Directors the timing of the handover to his successor as CEO and Managing Director.
Retirement of Director - Peter Turner
Peter Turner, an Executive Director of CSL, will be leaving the Company as an executive and, as a consequence, retiring as a director of CSL as of 17 October 2012.